Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens
Authors: Telzak, E. E.1; Chirgwin, K. D.2; Nelson, E. T.3; Matts, J. P.3; Sepkowitz, K. A.4; Benson, C. A.5; Perlman, D. C.6; El-Sadr, W. M.7; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); AIDS Clinical Trials Group (ACTG), National Institutes for Health
Source: The International Journal of Tuberculosis and Lung Disease, Volume 3, Number 4, April 1999 , pp. 337-343(7)
Abstract:SETTING: Mortality associated with human immunodeficiency virus (HIV) related multidrug-resistant tuberculosis (MDR-TB) is reduced with effective early therapy. Identifying predictors of, and effective regimens for, MDR-TB is critical.
OBJECTIVE: A multicenter prospective study was initiated to 1) determine the demographic, behavioral, clinical and geographic risk factors associated with the occurrence of MDR-TB among HIV-infected patients, and 2) to evaluate the overall survival and clinical response of MDR-TB patients treated with specific drug regimens.
METHODS: Patients were prospectively evaluated for MDR-TB. Information included history of prior treatment for tuberculosis, close contact with a known case of MDR-TB, and residence in a facility with known or suspected MDR-TB transmission. Patients with known MDR-TB, or those suspected to be at high risk, were offered enrollment in a treatment pilot study. Study drugs included levofloxacin and at least two additional drugs to which the patient's isolate was known, or most likely, to be susceptible. Survival was the primary endpoint.
RESULTS: Complete data are available for 156 HIV-infected patients with confirmed tuberculosis. Sixteen (10%) had MDR-TB. Only a history of prior tuberculosis treatment was associated with MDR-TB in multivariate analysis (OR = 4.4, P < 0.02). Twelve patients with MDR-TB enrolled in the treatment pilot had a median CD4 cell count of 51/mm3. The cumulative probability of survival at one year was 75% (95% CI 50.5–99.5) and at 18 months, 65.6% (95% CI 38.1–93.1). Toxicity requiring discontinuation of medications occurred in two patients.
CONCLUSIONS: A history of treatment for tuberculosis was the only predictor for MDR-TB in a cohort of HIV-infected patients with tuberculosis. In addition, this prospective study supports the results of prior retrospective studies that effective treatment impacts on mortality. Current second-line treatment, including high dose levofloxacin, appears to be reasonably well tolerated.
Document Type: Regular Paper
Affiliations: 1: Bronx-Lebanon Hospital Center, Bronx, New York, USA 2: SUNY Health Science Center at Brooklyn, New York, USA 3: CPCRA Statistical Center, Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA 4: Memorial Sloan-Kettering Cancer Center, New York, New York, USA 5: Rush-Presbyterian—St. Luke's Medical Center, Chicago, Illinois, USA 6: Beth Israel Medical Center, New York, New York, USA 7: Harlem Hospital Center, Columbia University College of Physicians & Surgeons, New York, New York, USA
Publication date: April 1, 1999
- The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- ingentaconnect is not responsible for the content or availability of external websites
- In this: publication
- By this: publisher
- In this Subject: Internal Medicine
- By this author: Telzak, E. E. ; Chirgwin, K. D. ; Nelson, E. T. ; Matts, J. P. ; Sepkowitz, K. A. ; Benson, C. A. ; Perlman, D. C. ; El-Sadr, W. M. ; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) ; AIDS Clinical Trials Group (ACTG), National Institutes for Health